CD8A and neoplasm: In the tumor, ACT+MS-275 treatment reduced the frequency of CD11b+ DCs, while increasing the frequency of CD8+ and CD103+ DCs (Figure 3D); in dLNs however, we detected a reduced frequency of CD103+ DCs (Figure 3E).